Bosnian Journal of Basic Medical Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2024-03-25 ms1000000491303706 来自内蒙古

.

8 0

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2024-02-21 ms6000000177436004 来自江苏省

无

12 0

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2024-02-14 ms3000002075888164 来自安徽省

审稿速度:1.0
偏重的研究方向：肿瘤
经验分享：速度很快

11 0

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2022-10-11 ms3000000995770335

审稿速度:2.0 | 投稿命中率:50.0
经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的.

30 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2023-10-04 14718874m55(暂无昵称) 来自辽宁省

改名字今年没影响因子对晋升有影响吗

48 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2022-11-29 ms5000000575328523 来自山西省

审稿速度:1.0 | 投稿命中率:5.0
经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。

1 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2023-01-30 dfzzv 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：药物
经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！

33 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2023-07-14 默默0606 来自北京

请问这个杂志必须提前准备每位作者的ORCID账号么

24 0

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2023-07-12 ms4000001672420063 来自纽约

1

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2195127, encodeId=deec219512e60, content=., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ff89229551, createdName=ms1000000491303706, createdTime=Mon Mar 25 00:37:22 CST 2024, time=2024-03-25, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2188515, encodeId=775a21885152c, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=511d5601208, createdName=ms6000000177436004, createdTime=Wed Feb 21 15:13:15 CST 2024, time=2024-02-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187338, encodeId=4a92218e33857, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：速度很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd909164403, createdName=ms3000002075888164, createdTime=Wed Feb 14 23:02:01 CST 2024, time=2024-02-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2093206, encodeId=aabc20932066e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：研究方向临床模型转换研究 7.16号投稿 9.13给的大修，五个审稿人20多个问题，有好多个都是互动性问题和文章没什么关系（其实没什么要修的都是些小问题，主要是要喊润色） 9.20号反了回去 26号主编问了一些他没看懂的一些问题 9.27号接受虽然分不高，但总体来说还是比较严格的., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Tue Oct 11 20:50:24 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2160940, encodeId=40a72160940d5, content=改名字今年没影响因子对晋升有影响吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Wed Oct 04 20:15:09 CST 2023, time=2023-10-04, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2103331, encodeId=3475210333148, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿难度挺大的，投稿之后大多数都会在一天之内就给出回复（拒稿），有进展的话第二天会请到很多审稿人（超过一百），最后会收到五六位审稿人的意见，意见很专业，语言要求也挺高，杂志发文量不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88798384013, createdName=ms5000000575328523, createdTime=Tue Nov 29 16:41:07 CST 2022, time=2022-11-29, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2112108, encodeId=ccda2112108a8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药物 经验分享：刚中了一篇，这个杂志是个老刊了，今年换名字了，由《Bosnian Journal of Basic Medical Sciences》 [BJBMS] 改成《Biomolecules and Biomedicine》 [BB]，希望杂志越办越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ad1642788, createdName=dfzzv, createdTime=Mon Jan 30 12:49:12 CST 2023, time=2023-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2148038, encodeId=beab214803827, content=请问这个杂志必须提前准备每位作者的ORCID账号么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jul 14 16:28:13 CST 2023, time=2023-07-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147728, encodeId=8b8f214e72866, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad248773662, createdName=ms4000001672420063, createdTime=Wed Jul 12 22:03:07 CST 2023, time=2023-07-12, status=1, ipAttribution=纽约), GetPortalCommentsPageByObjectIdResponse(id=2142533, encodeId=790221425337e, content=接收纯生信吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9048588526, createdName=ms9000001377282776, createdTime=Tue Jun 13 10:06:54 CST 2023, time=2023-06-13, status=1, ipAttribution=广东省)]

2023-06-13 ms9000001377282776 来自广东省

接收纯生信吗

29 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务